Tate & Lyle and APC Microbiome Ireland announce publication of intellectual property for synbiotic fiber technology

The synbiotic fiber technology has shown positive preliminary results in supporting metabolic health.

Tate & Lyle (London), in partnership with APC Microbiome Ireland, has announced the publication of its jointly filed international patent application for a synbiotic fiber technology, which has shown positive preliminary results in supporting metabolic health. The technology combines the probiotic Lactobacillus mucosae with Tate & Lyle’s proprietary soluble dietary fiber called Promitor fiber. According to their press release, the combination could lead to several metabolic health benefits, including heart health, weight management, liver health, potentially improving immunity, lowering inflammation markers, and improving gut health.

The patent application is the result of an ongoing partnership between the two parties, which was recently expanded and extended in order to explore the potential metabolic pathways affecting the relationship between the microbiome and health.

“We are delighted, following our initial two-year research project with APC Microbiome, to have our joint patent application published for this ingredient technology that uses our Promitor fiber. The health benefits this new synbiotic fiber ingredient could bring, such as improving heart health and tackling obesity, are exciting and another step on our journey to live our purpose of Transforming Lives through the Science of Food,” said Kavita Karnik, PhD, global head, Nutrition & Regulatory Affairs at Tate & Lyle, in a press release. “As a science-driven organization, we are pleased to be continuing our research with APC Microbiome Ireland, looking into the gut microbiome and the positive role fibers can play in improving our health.”